BLAINJECTIONINJECTABLE
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
22
Data completeness
5/8 — Partial
TRULICITY (dulaglutide) by Eli Lilly and Company is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2014.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRULICITY (dulaglutide) is a GLP-1 receptor agonist administered via weekly subcutaneous injection developed by Eli Lilly and Company. It is indicated for the treatment of type 2 diabetes mellitus and has demonstrated cardiovascular benefits in clinical trials. The drug works by mimicking glucagon-like peptide-1, enhancing insulin secretion and reducing glucagon in a glucose-dependent manner. TRULICITY is positioned as a foundational GLP-1 therapy in the diabetes treatment landscape alongside newer competitors.
$7.4BPart D
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (22)
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Started Dec 2025
20 enrolled
Type 2 Diabetes Mellitus (T2DM)
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Started Jan 2025
55 enrolled
Type 2 Diabetes
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Started Jul 2024
600 enrolled
Type2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Started Jan 2023
623 enrolled
T2DMType 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
Started Dec 2022
212 enrolled
Diabetes Mellitus, Type 2
Worked on TRULICITY at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.